Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pharmacogenetics

Showing results (1-10 of 992) with videos related to

Pageof 100
Sort By:
Pharmacogenetics|July 27, 2001
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liverT Lang, K Klein, J Fischer, et al.
Pharmacogenetics|July 4, 2001
The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirementJ van der Weide, L S Steijns, M J van Weelden, et al.
Pharmacogenetics|July 4, 2001
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cellsM Hitzl, S Drescher, H van der Kuip, et al.
Pharmacogenetics|July 4, 2001
Uteroglobin gene polymorphisms affect the progression of immunoglobulin A nephropathy by modulating the level of uteroglobin expressionY S Kim, D Kang, D Y Kwon, et al.
Pharmacogenetics|June 22, 1999
Four amino acid changes are associated with the Aldh3a1 locus polymorphism in mice which may be responsible for corneal sensitivity to ultraviolet lightT Shiao, P Tran, D Siegel, et al.
Pharmacogenetics|June 22, 1999
Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancerT Katoh, S Kaneko, S Takasawa, et al.
Pharmacogenetics|June 22, 1999
Low levels of p53 are associated with resistance to tetrachlorodibenzo-p-dioxin toxicity in DBA/2 miceA L Yang, A G Smith, R Akhtar, et al.
Pharmacogenetics|June 22, 1999
Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populationsL F Jorge, M Eichelbaum, E U Griese, et al.
Pharmacogenetics|September 2, 1999
Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction methodG F Chen, Y M Tang, B Green, et al.
Pharmacogenetics|September 2, 1999
A rare G2061 insertion affecting the open reading frame of CYP2D6 and responsible for the poor metabolizer phenotypeD Marez-Allorge, S W Ellis, J M Lo Guidice, et al.
Pageof 100

Showing results (1-10 of 992) with videos related to

Sort By:
Pageof 100
Pharmacogenetics|July 27, 2001
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liverT Lang, K Klein, J Fischer, et al.
Pharmacogenetics|July 4, 2001
The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirementJ van der Weide, L S Steijns, M J van Weelden, et al.
Pharmacogenetics|July 4, 2001
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cellsM Hitzl, S Drescher, H van der Kuip, et al.
Pharmacogenetics|July 4, 2001
Uteroglobin gene polymorphisms affect the progression of immunoglobulin A nephropathy by modulating the level of uteroglobin expressionY S Kim, D Kang, D Y Kwon, et al.
Pharmacogenetics|June 22, 1999
Four amino acid changes are associated with the Aldh3a1 locus polymorphism in mice which may be responsible for corneal sensitivity to ultraviolet lightT Shiao, P Tran, D Siegel, et al.
Pharmacogenetics|June 22, 1999
Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancerT Katoh, S Kaneko, S Takasawa, et al.
Pharmacogenetics|June 22, 1999
Low levels of p53 are associated with resistance to tetrachlorodibenzo-p-dioxin toxicity in DBA/2 miceA L Yang, A G Smith, R Akhtar, et al.
Pharmacogenetics|June 22, 1999
Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populationsL F Jorge, M Eichelbaum, E U Griese, et al.
Pharmacogenetics|September 2, 1999
Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction methodG F Chen, Y M Tang, B Green, et al.
Pharmacogenetics|September 2, 1999
A rare G2061 insertion affecting the open reading frame of CYP2D6 and responsible for the poor metabolizer phenotypeD Marez-Allorge, S W Ellis, J M Lo Guidice, et al.
Pageof 100